BSP Medical Ltd. Information

BSP Medical is a ground-breaking digital health-tech company that developed the HyperQ technology, a suite of algorithms implemented in software for the diagnosis and monitoring of ischemic heart disease – the no. 1 killer in the world. BSP Medical provides in-depth and unique clinical value, bringing a new dimension into ECG diagnosis and monitoring. The HyperQ technology is a suite of algorithms implemented in software, aimed at the early detection of coronary artery disease (CAD) and cardiac conditions. HyperQ can be applied in any venue and on any monitoring or diagnostic platform such as standard rest and stress ECG devices or wearables devices. HyperQ demonstrated a unique predictive value for Major Adverse Cardiac Events (MACE), and an early detection capabilities of coronary artery disease on any resting ECG system. It provides a new perspective to the clinical staff, including diagnosis of Non-ST Elevation MI (NSTEMI) and Unstable Angina (UA). HyperQ offers an innovative, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease (IHD) and Acute Coronary Syndrome (ACS). HyperQ is a proprietary and patented technology. It analyses the high-frequency QRS depolarization segment of the cardiac cycle, whereas conventional ECG analysis of the ST segment is related to the repolarization phase of the cycle. HyperQ provides superior clinical accuracy to any other non-invasive solution currently available. HyperQ analyses ECG data and issues a clinical report. It can be installed on the cloud, as a stand-alone module on a PC or be integrated in an ECG system. The American Heart Association (AHA) included High Frequency QRS analysis in its last statement on exercise standards for testing (published in August 2013), pointing out that it has been found to have useful test performance for detection of coronary artery disease. HyperQ is FDA cleared and CE marked.